Loading...
•
Dec 31, 2025
Puma Biotechnology Q4 2025 Earnings Report
Puma Biotechnology reported its fourth quarter 2025 financial results, showing continued profitability and revenue growth driven by NERLYNX sales.
Key Takeaways
Puma Biotechnology achieved its third consecutive year of profitability in 2025. For Q4 2025, the company reported total revenue of $75.5 million, a significant increase from $59.1 million in Q4 2024, primarily due to higher product and royalty revenues. While GAAP net income decreased year-over-year due to tax valuation allowance adjustments, the company maintained a strong cash position and significantly reduced its total debt.
Total revenue for Q4 2025 grew to $75.5 million, up from $59.1 million in the prior year period.
Product revenue from NERLYNX reached $59.9 million in Q4, representing approximately 10% year-over-year growth.
Total debt was significantly reduced to $22.5 million at year-end 2025, down from $67.0 million at the end of 2024.
The company provided positive full-year 2026 guidance, forecasting net income between $10 million and $13 million.
Revenue by Segment
Forward Guidance
Puma provided a financial outlook for Q1 2026 and Full Year 2026, projecting continued profitability and steady revenue.
Positive Outlook
- Full year 2026 total revenue is guided between $214 million and $221 million.
- Full year 2026 net income is expected to be between $10 million and $13 million.
- Anticipated presentation of interim data from ALISCA-Breast1 Phase II trial in Q2 2026.
- Anticipated presentation of interim data from ALISCA-Lung1 Phase II trial in Q2 2026.
- Updated data from ALISCA-Breast1 expected in Q4 2026.
Challenges Ahead
- Q1 2026 is projected to result in a net loss between $8 million and $10 million.
- Full year 2026 royalty revenue is guided lower ($20M-$23M) than 2025 actuals ($24.3M).
- Gross to Net Adjustment for Q1 2026 is expected to be high at 29.5%–30.5%.
- License revenue is projected to be $0 for the full year 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...